BMY
NYSEBristol-Myers Squibb Company
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks71+30%
2026-04-192026-10-11
Mix3390d
- Other14(42%)
- Insider11(33%)
- Earnings3(9%)
- SEC Filings2(6%)
- Analyst2(6%)
- Dividends1(3%)
Latest news
25 items- PRBristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETsThe study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression free survival (PFS) Bristol Myers Squibb (NYSE:BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb company. The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival by blinded independent central review, and safety results consistent with the known RYZ101 safety profile. ACTION-1 is a randomized Phase 3 clinical trial evaluating RYZ101 (225Ac-DOTATATE) versus investigator's choic
- PRBristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary EndpointIn the trial, admilparant at the 60 mg dose demonstrated a statistically significant benefit in absolute change in forced vital capacity (FVC) from baseline to Week 52 compared with placebo Admilparant demonstrated a favorable safety and tolerability profile The totality of the findings supports the potential of admilparant as a clinically meaningful first-in-class treatment Bristol Myers Squibb (NYSE:BMY) today announced topline results from the pivotal Phase 3 ALOFT-IPF trial evaluating the efficacy, safety and tolerability of admilparant, a potential first-in-class, orally administered, potent and selective lysophosphatidic acid receptor 1 (LPA1) antagonist, in adults with idiopath
- PRBristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...In the EXCALIBER study, results showed a progression-free survival hazard ratio of 0.49 compared with daratumumab, bortezomib and dexamethasone Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3 EXCALIBER-RRMM Study Bristol Myers Squibb (NYSE:BMY) today announced positive topline results from the Phase 3 EXCALIBER-RRMM study, evaluating ZENBEXUSTM (iberdomide) in combination with daratumumab and dexamethasone (ZDd) in 800 patients with multiple myeloma (MM), as early as first relapse. Results showed Z
- INSIDERSEC Form 4 filed by Bristol-Myers Squibb Company4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- ANALYSTBristol-Myers downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Bristol-Myers from Outperform to Market Perform and set a new price target of $59.00
- INSIDERSEC Form 4 filed by Director Yale Phyllis R4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- INSIDERSEC Form 4 filed by Director Samuels Theodore R. Ii4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- INSIDERSEC Form 4 filed by Director Rice Derica W4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcmullen Michael R.4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- INSIDERSEC Form 4 filed by Director Arduini Peter J4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- PRBristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care MovementSecond-Year Champions in Care Campaign Introduces $1 Million Community Grant Program for Medically Underserved CommunitiesBristol Myers Squibb (NYSE:BMY) today announced the expansion of Champions in Care, the company's initiative honoring healthcare professionals (HCPs), first launched in 2025. Now in its second year, the campaign builds on its inaugural effort that celebrated HCPs across therapeutic areas through digital, social and live engagement. This year's expansion introduces new opportunities for HCPs to extend their impact beyond patient care and into the communities they serve.As part of this year's campaign, Bristol Myers Squibb will award $1 million in grants to nonprofit organi
- PRU.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*CAMZYOS is the only FDA-approved therapy for the treatment of oHCM in a pediatric population Approval based on positive results of Phase 3 SCOUT-HCM trial, building on the extensive clinical evidence for CAMZYOS in adults with oHCM Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) approved CAMZYOS® (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more. CAMZYOS now has the broadest indication of any cardiac myosin inhibitor (CMI). This expanded indication offers a new treatment option for patient
- PRBristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple MyelomaResults presented at IMS 2026 show ZENBEXUS in combination with daratumumab and dexamethasone doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41.1% vs. 20.7%) Data reinforce the value of the ZENBEXUS-based triplet as an effective, easily administered treatment option for patients with relapsed or refractory multiple myeloma as early as first relapse Results simultaneously published in The Lancet Oncology Bristol Myers Squibb (NYSE:BMY) today announced first time presentation of results from the prespecified analysis of the pivotal Phase 3 EXCALIBER-RRMM trial (NCT04975997) evaluating ZENBEXUS™ (iberdomide) in combinat
- PRBristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2026 on Thursday, October 29, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.Investors and the general public are invited to listen to a live audio webcast of the call at http://investor.bms.com. Materials related to the call will be available on the company’s Investor Relations website prior to the start of the conference call.A replay of the webcast will be available here approximately three hours after the conference call concludes.About Bristol Myers Squibb: Transforming Patients’ Lives Through ScienceAt Bristol Myers Squi
- PRBristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two YearsResults from the POETYK PsA-2 open-label extension demonstrated robust response rates in patients treated with Sotyktu, with clinical responses continuing to improve through year one and maintained through year twoTwo-year data build on the proven efficacy and safety profile of Sotyktu as the only approved tyrosine kinase 2 (TYK2) inhibitor for adults with psoriatic arthritisBristol Myers Squibb (NYSE:BMY) today announced positive results through two years of treatment from the Phase 3 POETYK PsA-2 study, including its open-label extension (OLE), showing durable efficacy and a consistent safety profile for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis. These data are be
- PRBristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on November 2, 2026, to stockholders of record at the close of business on October 2, 2026. About Bristol Myers Squibb: Transforming Patients’ Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb,
- INSIDEREVP,Chief Med Offr,Head of Dev Massacesi Cristian sold $403,498 worth of shares (6,249 units at $64.57), decreasing direct ownership by 25% to 18,748 units (SEC Form 4)4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- PRHistoric First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics MarketAUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ:QNTM) (profile) has received U.S. Food and Drug Administration ("FDA") clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class
- PRBristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate in this heavily pretreated patient population who have been exposed to a prior BCMA-targeted therapy QUINTESSENTIAL is the first pivotal trial to evaluate a therapy in quadruple-class exposed relapsed and refractory multiple myeloma patients following treatment with prior BCMA-targeted therapies Arlocabtagene autoleucel is a potential best-in-class autologous GPRC5D-directed CAR T cell therapy Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene
- INSIDEREVP, Corporate Affairs Short Bartie Wendy exercised 1,236 shares at a strike of $66.92 and covered exercise/tax liability with 633 shares, increasing direct ownership by 5% to 12,684 units (SEC Form 4)4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- PRBristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026New single-arm, open-label data extend the body of evidence supporting consistent clinical benefit and safety with Camzyos, adding to the longest-running clinical development experience for a cardiac myosin inhibitor (CMI) in symptomatic oHCM Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings Bristol Myers Squibb (NYSE:BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. EXPLORER-LTE is the largest and longest evaluation of symptomatic obstructive hypertrop
- INSIDERSVP and Controller Holzer Phil M sold $33,750 worth of shares (500 units at $67.50), decreasing direct ownership by 3% to 16,862 units (SEC Form 4)4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- PRA Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityNEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is surprisingly straightforward: instead of giving the immune system a one-size-fits-all treatment, an mRNA vaccine can be designed to teach it what a particular tumor looks like and help it go after those cancer cells. That matters in lung cancer because every tumor can be different, and some eventually learn how to get around existing treatments. Researchers are now looking at whether personalized mRNA vaccines can work alongside today’s immunotherapies to give the immune system a
- PRU.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First RelapseApproval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment class, representing the next chapter in Bristol Myers Squibb’s targeted protein degradation platform Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of thera
- PRAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationSAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE:BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration. "Atrium's vision is to deliver treatments that address the underlying cause of serious heart disease, including rare genetic cardiomyopathies," said Kathleen Gallagher, Pres
BMY FAQ
7 questionsWhat does Bristol-Myers Squibb Company do?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and...Where does BMY stock trade?
Bristol-Myers Squibb Company (BMY) is listed on NYSE.What sector and industry is BMY in?
Bristol-Myers Squibb Company operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does BMY pay a dividend?
BMY's most recent ex-dividend date was 2026-10-02 with a cash dividend of $0.63 per share. No future ex-date is on file yet.What are analysts saying about BMY?
Bristol-Myers Squibb Company has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Market Perform on 2026-10-05. Recent price targets cluster around $4500.00.What companies are similar to BMY?
Notable peers in the same industry include JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG), AZN (AstraZeneca PLC). Compare BMY side-by-side with any of them on Quantisnow.How can I track BMY on Quantisnow?
Quantisnow aggregates Bristol-Myers Squibb Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BMY to receive live email and push alerts on every new disclosure.